Overview
About Vascarta Inc.
Vascarta Inc. is a clinical-stage pharmaceutical company designed to increase therapeutic effectiveness while improving the patient experience.
Vascarta is innovating treatments for chronic diseases via transdermal loading of drugs into circulating blood cells for targeted anti-inflammatory activity. We have three core assets:
1) VASPORTA™ TRANSDERMAL DELIVERY - A patented topical system that enhances absorption, bypasses oral bioavailability issues, and offers a needle-free alternative to injections.
2) OUR LEAD PRODUCT CANDIDATE: VAS-101 - Harnesses the established anti-inflammatory and pain-relieving properties of curcumin through transdermal delivery which overcomes the limited bioavailability and suboptimal effectiveness of oral dosing. Phase 1 clinical trials for Sickle Cell Disease and Osteoarthritis initiated 1Q2025 with expected completion by 4Q2025.
3) TARGETED CANCER THERAPEUTICS - Novel linker chemistry licensed from CUNY that combines curcumin with approved cancer drugs to improve efficacy and reduce side effects.
Vascarta is innovating treatments for chronic diseases via transdermal loading of drugs into circulating blood cells for targeted anti-inflammatory activity. We have three core assets:
1) VASPORTA™ TRANSDERMAL DELIVERY - A patented topical system that enhances absorption, bypasses oral bioavailability issues, and offers a needle-free alternative to injections.
2) OUR LEAD PRODUCT CANDIDATE: VAS-101 - Harnesses the established anti-inflammatory and pain-relieving properties of curcumin through transdermal delivery which overcomes the limited bioavailability and suboptimal effectiveness of oral dosing. Phase 1 clinical trials for Sickle Cell Disease and Osteoarthritis initiated 1Q2025 with expected completion by 4Q2025.
3) TARGETED CANCER THERAPEUTICS - Novel linker chemistry licensed from CUNY that combines curcumin with approved cancer drugs to improve efficacy and reduce side effects.